These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36933851)

  • 1. Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021.
    Silva-Valencia J; Soto-Becerra P; Escobar-Agreda S; Fernandez-Navarro M; Moscoso-Porras M; Solari L; Mayta-Tristán P
    Travel Med Infect Dis; 2023; 53():102565. PubMed ID: 36933851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021.
    Katz MA; Rojas Castro MY; Chakhunashvili G; Chitadze N; Ward CL; McKnight CJ; Lucaccioni H; Finci I; Zardiashvili T; Pebody R; Kissling E; Sanodze L
    PLoS One; 2024; 19(9):e0307805. PubMed ID: 39240827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study.
    Barzegar M; Manteghinejad A; Afshari-Safavi A; Mirmosayyeb O; Nasirian M; Bagherieh S; Mazaheri S; Rahimi M; Zabeti A; Javanmard SH; Shaygannejad V
    Mult Scler Relat Disord; 2023 Mar; 71():104548. PubMed ID: 36827877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data.
    Silva-Valencia J; Soto-Becerra P; Escobar-Agreda S; Fernandez-Navarro M; Elorreaga OA; Mayta-Tristán P; Mezones-Holguin E; Solari L
    Vaccine; 2022 Oct; 40(45):6512-6519. PubMed ID: 36202642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
    Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
    Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
    Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV
    PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
    Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
    Nadeem I; Ul Munamm SA; Ur Rasool M; Fatimah M; Abu Bakar M; Rana ZK; Khatana UF; Jordon L; Saqlain M; Mahdi N; McLoughlin H
    Postgrad Med J; 2023 Jun; 99(1171):463-469. PubMed ID: 37294716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
    Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
    J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
    Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
    Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Aragón-Ayala CJ; Benítes-Zapata VA
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru.
    Montero S; Urrunaga-Pastor D; Soto-Becerra P; Cvetkovic-Vega A; Guillermo-Roman M; Figueroa-Montes L; Sagástegui AA; Alvizuri-Pastor S; Contreras-Macazana RM; Apolaya-Segura M; Díaz-Vélez C; Maguiña JL
    Vaccine X; 2023 Aug; 14():100311. PubMed ID: 37207103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.